Welcome to Pharma Unlimited, by Wolters Kluwer. Join host Bertrand Bodson as we go under the microscope to examine some of the biggest issues facing the pharma sector. What will the arrival of Big Tech mean for innovation, risk, and regulation? How will the industry develop new treatments in a post-pandemic world? This five-part series will feature some of the leading lights in life sciences and technology and explore some of the biggest questions facing the pharma industry.
All content for Pharma Unlimited is the property of Wolters Kluwer and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Welcome to Pharma Unlimited, by Wolters Kluwer. Join host Bertrand Bodson as we go under the microscope to examine some of the biggest issues facing the pharma sector. What will the arrival of Big Tech mean for innovation, risk, and regulation? How will the industry develop new treatments in a post-pandemic world? This five-part series will feature some of the leading lights in life sciences and technology and explore some of the biggest questions facing the pharma industry.
Sir John Bell, Regius Professor of Medicine at Oxford University, joins Bertrand Bodson on the latest episode of the Pharma Unlimited podcast. Sir John founded the Wellcome Trust Centre for Human Genetics, and most recently led the program for the AstraZeneca-Oxford COVID-19 vaccine. Sir John tells the story of the Oxford vaccine, and takes a closer look at how the pharma industry might handle risk differently in the future.
Pharma Unlimited
Welcome to Pharma Unlimited, by Wolters Kluwer. Join host Bertrand Bodson as we go under the microscope to examine some of the biggest issues facing the pharma sector. What will the arrival of Big Tech mean for innovation, risk, and regulation? How will the industry develop new treatments in a post-pandemic world? This five-part series will feature some of the leading lights in life sciences and technology and explore some of the biggest questions facing the pharma industry.
